Maegim한국어

리가켐바이오

141080KOSDAQSector: Pharma & Biotech
₩93,600 3.60%Market cap ₩3.47TAs of Jul 21, 2026 close · updated once daily
C
Grade C44.6 ptsTop 63% of 2,523 stocks
Financial strength
55.0
Growth momentum
45.1
Price attractiveness
32.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

55.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
29.7%
Above median · Top 29.1% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
853.5%
Above median · Top 16.9% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-75.2%
Below median · Top 71% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-16.9%
Below median · Top 63.2% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

45.1
How much did revenue grow in a year?
Revenue growth (YoY)
12.4%
Above median · Top 34.5% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
61.8%
Above median · Top 6.9% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-409.2%
Below median · Top 95.3% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-111.4%
Below median · Top 83.1% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

32.3
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 54.7% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
6.83x
Below median · Top 80.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15